Online inquiry

IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3205MR)

This product GTTS-WQ3205MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3205MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12460MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ3129MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ2357MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ13381MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ12265MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ7774MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ6645MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ5982MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CLLB8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW